Journal Image
CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)
ISSN (Print): 1871-5273
ISSN (Online): 1996-3181
Epub Full Text Article
DOI: 10.2174/1871527312666131223113900      Price:  $95

Wnt/β-Catenin Signaling in Alzheimer’s Disease

Author(s): GV De Ferrari, ME Avila, MA Medina, E Pérez-Palma, BI Bustos and MA Alarcón
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by a deficit in cognitive processes that are clinically manifested as alterations in memory, judgment and reasoning. We proposed earlier that sustained loss of function of Wnt/β- catenin signaling underlies the onset and progression of AD. Here, we discuss recent developments in the field regarding the involvement of Wnt/β-catenin signaling components in amyloid precursor protein processing, Aβ peptide neurotoxicity, τ phosphorylation and modulation of Apolipoprotein E effects in the brain. In summary, data accumulated during the past decade confirm some important predictions of our hypothesis where components of this signaling cascade are actively engaged in the events leading to AD neuropathology and that compounds that mimic activation of this signaling cascade, such as lithium, should be considered for therapeutic intervention in Alzheimer's patients
Alzheimer’s disease, amyloid precursor protein, tau, apolipoprotein E, Wnt/β-catenin signaling, lithium
Center for Biomedical Research and FONDAP Center for Genome Regulation. Universidad Andres Bello, Republica #239, PO Box 8370134, Santiago, Chile